Last reviewed 2026-04-20 · How we verify

Aziridinylbenzoquinone (DIAZIQUONE)

Phase 2 active Small molecule

Aziridinylbenzoquinone (generic name: DIAZIQUONE) is a diaziquone drug. It is currently in Phase 2 development.

Diaziquone works by inducing DNA cross-links and strand breaks, leading to cell death.

Aziridinylbenzoquinone (Diaziquone) is a small molecule diaziquone with unknown target and mechanism of action. It is not FDA-approved for any indications. The commercial status of Diaziquone is unclear, and it is not known whether it is patented or available as a generic. Diaziquone is a chemotherapeutic agent that has been investigated for its potential to treat various types of cancer, but its development has been limited due to its toxicity profile. Further research is needed to fully understand the potential benefits and risks of this compound.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Oncology Phase 2 attrition -2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DIAZIQUONE
Drug class	diaziquone
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 2

Mechanism of action

Imagine your DNA as a long, twisted ladder. Diaziquone is like a chemical that goes into the ladder and causes it to break, making it impossible for the cell to function. This ultimately leads to the death of the cell, which can be beneficial in treating cancer.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Aziridinylbenzoquinone CI brief — competitive landscape report
Aziridinylbenzoquinone updates RSS · CI watch RSS

Frequently asked questions about Aziridinylbenzoquinone

What is Aziridinylbenzoquinone?

Aziridinylbenzoquinone (DIAZIQUONE) is a diaziquone drug.

How does Aziridinylbenzoquinone work?

Diaziquone works by inducing DNA cross-links and strand breaks, leading to cell death.

What is the generic name of Aziridinylbenzoquinone?

DIAZIQUONE is the generic (nonproprietary) name of Aziridinylbenzoquinone.

What drug class is Aziridinylbenzoquinone in?

Aziridinylbenzoquinone belongs to the diaziquone class. See all diaziquone drugs at /class/diaziquone.

What development phase is Aziridinylbenzoquinone in?

Aziridinylbenzoquinone is in Phase 2.

Drug class: All diaziquone drugs
Therapeutic area: All drugs in Oncology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing